Prurigo Nodularis Treatment Market Size & Share 2025 – 2034

Prurigo Nodularis Treatment Market Size

The global prurigo nodularis treatment market was valued at USD 2.1 billion in 2024. The market is expected to grow from USD 2.2 billion in 2025 to USD 3.1 billion in 2034, at a CAGR of 4.1% during the forecast period. The market is steadily gaining momentum, fueled by a combination of growing incidence of the disease, increased awareness of available treatments, and notable advancements in biologic drug development.

For example, the National Organization of Rare Disorders (NORD) reports that PN affects roughly 72 individuals per 100,000 annually in the U.S., equating to approximately 87,634 new adult cases each year among those aged 18 to 64. This growing disease burden, particularly among individuals with pre-existing dermatological conditions such as atopic dermatitis, is intensifying the demand for effective therapeutic interventions.
 

PN significantly affects adults with age 20 to 60 and is generally linked to systemic health issues, including hepatic and renal dysfunction, neurological disorders, and chronic inflammatory skin diseases like eczema and bullous pemphigoid. The increasing diagnosis rate, heightened awareness among both healthcare professionals and patients, and the severely debilitating nature of PN are other factors propelling market expansion. In response to this escalating need, global research and development efforts have gained momentum. Pharmaceutical companies are making substantial investments in innovative therapies designed to disrupt the itch–scratch cycle and address the underlying inflammatory mechanisms of PN.
 

For instance, in November 2020, the U.S. FDA granted breakthrough therapy designation to Vixarelimab, a monoclonal antibody that targets the oncostatin M receptor beta (OSMRβ), for the treatment of pruritus associated with PN. These regulatory designations not only facilitate in reducing the duration of approval but also demonstrate the promising therapeutic potential of emerging drugs, thereby boosting confidence among clinicians and investors.
 

In addition, increased funding from government agencies and private investors, along with strategic efforts by leading pharmaceutical companies to develop targeted biologics, is opening up new opportunities for market expansion. The introduction of approved biologics such as Dupilumab and recent regulatory clearances for therapies like Nemolizumab are reinforcing the treatment landscape. These advanced therapies offer more effective solutions compared to conventional treatments like corticosteroids and antihistamines, thereby accelerating market expansion.
 

Prurigo nodularis treatment encompasses a variety of therapeutic products aimed at managing and alleviating the symptoms of this chronic, intense skin disorder, which is characterized by firm, nodular lesions and persistent inflammation. These include majorly corticosteroids, antihistamines, biologics, emollients, and capsaicin cream, among others.
 

Prurigo Nodularis Treatment Market Trends

• The market is witnessing a significant transformation driven by a deeper understanding of its immunopathology and the growing demand for targeted therapies.
   
• The approval of biologics like dupilumab, which target the underlying inflammatory pathways, has significantly shaped the treatment landscape, with dermatologists increasingly favoring long-term immune modulation over symptom control alone.
   
• In addition, the increasing prevalence of prurigo nodularis is a primary factor supporting the growth of the market, as each newly diagnosed patient represents a sustained need for both symptom relief and disease-modifying therapies. 
   
• The defining feature of PN, that is the persistent, treatment-resistant itch, leads to sleep disturbances, heightened anxiety, and social isolation, prompting affected individuals to actively pursue effective treatments and remain open to innovative options that offer long-term relief.
   
• As reported by the National Organization of Rare Disorders (NORD), PN exhibits distinct demographic clustering that broadens its market reach beyond a single niche group.  Women tend to experience more intense pruritus, which often necessitates stronger or combination therapies.
   
• Age also plays a critical role, although PN can develop at any stage of life, it is most frequently diagnosed between the ages of 40 and 69, a period marked by increased healthcare engagement and dermatology consultations, thereby improving case detection and treatment rates. Different comorbidities in such aging populations further contribute to the rising prevalence of prurigo nodularis.
   
• Furthermore, PN is significantly more common in individuals living with HIV, and younger patients frequently present with concurrent atopic or allergic conditions such as eczema. These overlapping disease burdens magnify itch severity and complicate management, pushing healthcare providers towards systemic immunomodulators and newly approved biologics that can address multiple inflammatory pathways at once.
   
• Another prominent trend is the surge in clinical research and pipeline activity. Several investigational therapies, including nemolizumab, vixarelimab, and JAK inhibitors, are in various stages of clinical trials, reflecting strong pharmaceutical investment in addressing this condition. The success of these trials is expected to diversify the therapeutic landscape and offer more personalized options for patients with moderate-to-severe PN.
   

Prurigo Nodularis Treatment Market Analysis

In 2021, the global market was valued at USD 2.04 billion and experienced growth to reach USD 2.07 billion in 2022 and USD 2.1 billion in 2023.
 

Based on the product type, the global market is segmented into corticosteroids, antihistamines, emollients, capsaicin cream, biologics, calcineurin inhibitors, immunosuppressants, and other product types. The corticosteroids segment dominated the market and was valued at USD 650.4 million in 2024.
 

• The dominance of this segment is primarily attributed to corticosteroids being the longstanding first-line therapy for alleviating inflammation and severe itching associated with PN.
   
• Topical corticosteroids are especially prescribed by dermatologists due to their strong anti-inflammatory and immunosuppressive properties, which provide rapid symptom relief.
   
• Because of their cost-effectiveness, accessibility, and familiarity with healthcare providers, corticosteroids are widely used for both the initial phase of treatment and maintenance, particularly in mild to moderate PN cases, thus leading to their substantial market share.
   
• Moreover, they are available as both prescription and over-the-counter (OTC) drugs formulations, enhancing their usability in outpatient and self-managed care settings, thereby driving their market share.
   

Based on the route of administration, the global prurigo nodularis treatment market is classified into topical, oral, and parenteral. The topical segment held the highest market share of 55.3% in 2024.
 

• Topical therapies like corticosteroids, calcineurin inhibitors, capsaicin creams, and emollients are very effective for managing localized symptoms of PN since it primarily affects the skin.
   
• The ability to deliver medication directly to the affected areas, thereby reducing systemic side effects and improving patient adherence, makes these therapies a preferred choice for both patients and healthcare providers.
   
• Moreover, compared to systemic treatments, topical medications are usually more accessible and less expensive. Their availability in both prescription and over-the-counter forms, as well as their suitability for long-term maintenance in mild to moderate PN cases, results in their high usage rates.
   

Based on the medication type, the global prurigo nodularis treatment market is categorized into prescription and OTC. The prescription segment is expected to grow at a significant CAGR of 3.8% during the forecast timeframe.
 

• The high growth of this segment is due to the increasing reliance on advanced and physician-guided therapies for managing this chronic and complex skin condition.
   
• As awareness of PN grows and more patients seek professional care for its severe symptoms, physicians are increasingly prescribing potent corticosteroids, immunosuppressants, calcineurin inhibitors, and biologics, which are only available via prescription. These treatments offer targeted action, longer-lasting relief, and are more suitable for moderate to severe cases that require continuous clinical monitoring.
   
• In addition, the development and regulatory approval of innovative biologic therapies such as nemolizumab and dupilumab are expected to result in a significant growth in the prescription segment.
   
• These biologics are not available over-the-counter because they are specifically designed to treat PN or chronic pruritus and require medical supervision.
   

Based on the distribution channel, the global prurigo nodularis treatment market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated in 2024 and is anticipated to reach USD 1.6 billion by 2034.
 

• PN is frequently diagnosed and treated by dermatologists or immunologists in clinical settings, where patients typically receive initial and ongoing treatments such as immunosuppressants, biologics, and corticosteroid injections from hospital-affiliated pharmacies. These settings facilitate close monitoring for side effects, accurate dosage administration, and adherence to treatment protocols, especially in cases of severe or treatment-resistant PN.
   
• Hospital pharmacies also tend to stock recently approved drugs and sophisticated biologics that aren't always easily accessible in stores or online. They serve both inpatient care and outpatient clinics linked to tertiary care centers, thereby expanding their reach.
   
• Furthermore, this segment benefits from robust reimbursement frameworks and centralized procurement systems, which streamline access to high-cost medications and enhance their market position.
   

The North America prurigo nodularis treatment market dominated the global market with a market share of 41.3% in 2024.
 

The U.S. market was valued at USD 783.5 million and USD 792.3 million in 2021 and 2022, respectively. The market size reached USD 816.6 million in 2024, growing from USD 803.6 million in 2023.
 

• This upward trend is primarily due to increased disease prevalence, easier access to dermatological care, and the development of innovative treatments such as immunomodulators and biologics that offer targeted, long-lasting relief.
   
• Additionally, A significant contributor to heightened awareness and market growth is the observance of World Prurigo Day in the U.S., scheduled for June 21, 2025. This initiative is focused on increasing public and clinical recognition of prurigo nodularis.
   
• The campaign seeks to improve patient care, foster collaboration among healthcare providers, and encourage research and innovation, particularly in regions like the U.S., where demand for effective treatment options is rising.
•  

Europe prurigo nodularis treatment market accounted for USD 609.4 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• The increasing number of patients affected with chronic pruritic conditions, along with advancements in dermatological care, has increased the adoption of PN treatment in the region.
   
• European countries have also seen a rise in referrals to dermatology specialists, particularly for rare and severe skin conditions like PN, thereby fueling market demand for prescription-based and advanced therapies.
   
• The approval of Galderma's Nemluvio (nemolizumab), a novel biologic therapy for moderate-to-severe prurigo nodularis and atopic dermatitis, by the European Union is a significant milestone bolstering this market growth.
   

Germany prurigo nodularis treatment market is anticipated to witness considerable growth over the analysis period.
 

• Germany has one of the highest physician densities and healthcare access rates in Europe, which makes it possible to diagnose and treat underdiagnosed conditions like PN.
   
• The prevalence of comorbid conditions like diabetes and atopic dermatitis, which are risk factors for PN, is increasing, which further contributes to the rise in patient numbers and presents opportunities for pharmaceutical companies and healthcare providers to expand their offerings in this high-potential market.
   
• Increasing referrals to dermatologists and increased disease awareness among patients and healthcare providers are driving up treatment rates, particularly with the availability of new targeted therapies.
   

The Asia Pacific prurigo nodularis treatment market is anticipated to grow at the highest CAGR of 4.4% during the analysis timeframe.
 

• In countries such as China, India, and Southeast Asia, the number of PN diagnoses is steadily increasing, due to better medical education, a greater emphasis on chronic skin conditions, and an increase in referrals to specialists.
   
• Early PN detection and treatment are becoming more common as public health systems increase their funding for dermatological care and awareness campaigns.
   
• Additionally, the region's growing middle-class population, increased healthcare spending, and rising burden of comorbidities such as atopic dermatitis, diabetes, and HIV, which are associated with PN, are expanding the target patient pool.
   

China prurigo nodularis treatment market is predicted to grow significantly over the forecast period.
 

• China's public health infrastructure has advanced significantly, especially in urban areas where access to specialized skin clinics and dermatology departments is improving.
   
• Furthermore, the demand for sophisticated dermatological care and prescription therapies has increased due to China's expanding middle class and rising out-of-pocket medical expenses.
   
• Additionally, the presence of a large number of local drug manufacturing companies in the country aids in market growth.
   

Brazil is expected to experience significant growth in the Latin America prurigo nodularis treatment market over the coming years.
 

• The Brazilian Society of Dermatology has been actively involved in raising awareness and promoting early detection, which is expected to increase the rate of clinical diagnosis and treatment.
   
• Furthermore, Brazil boasts a thriving pharmaceutical sector that produces both generic and branded medications in large quantities, lowering the cost and increasing access to treatments.
   
• Moreover, Brazil's urban centers have state-of-the-art medical facilities and specialty clinics that offer advanced treatments, thus enhancing the market growth.
   

Saudi Arabia prurigo nodularis treatment market is poised to witness substantial growth in Middle East and Africa market during the forecast period.
 

• The government’s Vision 2030 initiative includes significant investment in healthcare infrastructure, leading to the development of advanced hospitals and specialist care facilities.
   
• Furthermore, Saudi Arabia is experiencing greater access to specialty pharmaceuticals, including biologics and immunosuppressants, due to favorable regulatory changes and strategic partnerships with global pharma companies. These factors will positively drive the Saudi Arabia market.
   

Prurigo Nodularis Treatment Market Share

The global market is currently in a phase of evolution, with the competitive landscape shaped by a combination of established pharmaceutical giants and emerging specialty biotech firms. Historically, the market was dominated by topical corticosteroids, antihistamines, and emollients, but with the recent approval of targeted biologics such as Dupixent (Sanofi) and Nemluvio (Galderma), the focus is rapidly shifting toward systemic therapies with disease-modifying potential. As a result, the competitive dynamics are being redefined, particularly in regions like the U.S. and Europe where regulatory support and commercial access are strong.
 

The top 5 players including Sanofi, Galderma, Pfizer, GlaxoSmithKline, and Johnson & Johnson account for approximately 55% – 65% of the global market share. As clinical trials advance and new biologics or neuromodulators gain approval, market share is expected to redistribute, favoring companies with targeted and differentiated offerings for this highly underserved and complex condition.
 

Prurigo Nodularis Treatment Market Companies

Few of the prominent players operating in the prurigo nodularis treatment industry include:

• Bayer
• Galderma
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Pfizer
• Rugby Pharma
• Sanofi
• Takeda Pharmaceuticals
• Teva Pharmaceutical Industries
• Trevi Therapeutics
• VYNE Therapeutics
   
• Galderma’s dedicated dermatology focus, making it one of the few global pharma firms exclusively targeting skin diseases. In 2025 and 2024, it achieved a major milestone with the EU and U.S. approval of Nemluvio (nemolizumab) for prurigo nodularis, making it a frontrunner in targeted PN treatment.
   
• Sanofi’s has first-mover advantage with Dupixent (dupilumab), the first approved biologic for prurigo nodularis in multiple regions. This approval has not only transformed treatment for PN but also established Sanofi as a leader in IL-4/IL-13 inhibition across immunologic conditions. Sanofi’s extensive clinical trial network, proven scalability, and strong focus on immunodermatology have helped the company establish a strong position in the market.
   

Prurigo Nodularis Treatment Industry News

• In February 2025, Galderma announced that the European Commission approved Nemluvio for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis across the European Union (EU). The approval covers subcutaneous use of Nemluvio for patients aged 12 and older with atopic dermatitis who are eligible for systemic therapy, as well as adults with moderate-to-severe prurigo nodularis requiring systemic treatment. This dual indication approval significantly enhances Galderma’s market presence in the dermatology segment and positions the company as a key player in addressing chronic inflammatory skin conditions.
   
• In August 2024, Galderma announced that the U.S. Food and Drug Administration (FDA) approved Nemluvio (nemolizumab) in a pre-filled pen formulation for subcutaneous injection for the treatment of adults with prurigo nodularis. This approval strengthens Galderma’s foothold in the U.S. dermatology market and expands patient access through a convenient, self-administered treatment option, enhancing the company’s competitive advantage in the chronic pruritic skin disorder space.
   
• In September 2022, Sanofi announced the approval of Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. This approval marked a significant expansion of Sanofi’s immunology portfolio, enabling the company to tap into an underserved market segment with high unmet medical needs.
   

The prurigo nodularis treatment market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Corticosteroids
• Antihistamines
• Emollients
• Capsaicin cream
• Biologics
• Calcineurin inhibitors
• Immunosuppressants
• Other product types

Market, By Route of Administration

• Topical
• Oral
• Injectable

Market, By Medication Type

• Prescription
• OTC

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE